PERRIGO
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and… Read more
PERRIGO (PGO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.382x
Based on the latest financial reports, PERRIGO (PGO) has a cash flow conversion efficiency ratio of -0.382x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.06 Million) by net assets (€28.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PERRIGO - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how PERRIGO's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PERRIGO Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PERRIGO ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MY XUAN BRICK
VN:GMX
|
N/A |
|
Bayn Group AB (publ)
MU:B39
|
-0.010x |
|
TRINITY MIRROR
BE:MRR
|
N/A |
|
Rajoo Engineers Limited
NSE:RAJOOENG
|
N/A |
|
Finkurve Financial Services Limited
NSE:FINKURVE
|
N/A |
|
FHER3F
SA:FHER3F
|
N/A |
|
Triad Group PLC
LSE:TRD
|
0.245x |
|
bleuacacia ltd Warrants
NASDAQ:BLEUW
|
0.072x |
Annual Cash Flow Conversion Efficiency for PERRIGO (2019–2024)
The table below shows the annual cash flow conversion efficiency of PERRIGO from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €24.67 Million | €-29.14 Million | -1.181x | -11.51% |
| 2023-06-30 | €26.15 Million | €-27.69 Million | -1.059x | -136.49% |
| 2022-06-30 | €35.91 Million | €-16.08 Million | -0.448x | +60.26% |
| 2019-06-30 | €8.55 Million | €-9.63 Million | -1.127x | -- |